CLGN CollPlant Biotechnologies Ltd

Overview and Growth

CollPlant Biotechnologies Ltd generated $2.37M of revenue in fiscal 2025, with net loss of $11.49M and an operating cash outflow of $9.42M. Revenue of $2.37M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Revenue was 360.4% above fiscal 2024 revenue of $515.00K, marking a year-over-year increase. The company reported diluted EPS of -$0.94, adding a shareholder-level measure to the absolute income figures considered below. The diluted weighted-average share count was 12.20M, linking total earnings with the per-share result received by shareholders. The company employed $10.79M of total assets, the balance-sheet base supporting its current operating and cash-flow results. Revenue equaled 0.22x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

Gross profit was $1.54M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross profit represented 64.8% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $11.48M, reflecting costs that exceeded gross profit. The operating loss equaled 484.3% of revenue, showing the scale of the operating deficit relative to sales. The bottom-line result was a net loss of $11.49M after operating, financing, tax, and other recognized items. Net margin was -484.6%, reflecting a loss equal to 484.6% of reported revenue. EBITDA was negative $10.57M, showing a deficit before interest, taxes, depreciation, and amortization. The net loss equaled 188.9% of period-end equity, showing the deficit relative to book capital. The loss-to-assets relationship was 106.5%, placing the bottom-line deficit against the company’s resource base. The bottom-line deficit decreased from $16.61M in fiscal 2024 to $11.49M.

Liquidity and Capital Structure

The company held $10.79M of assets against $4.70M of liabilities and $6.08M of equity, revealing how the asset base was financed. At period end, current assets of $6.75M compared with current liabilities of $2.67M, defining the company’s short-term resource position. The current ratio was 2.53x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Cash and equivalents totaled $5.59M, identifying the most liquid reported component available within the broader current-asset balance. Cash and equivalents represented 209.2% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The equity-to-assets relationship was 56.4%, placing book capital against the total resource base. Liabilities represented 43.6% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 51.8% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 42.4% lower than fiscal 2024 assets of $18.71M, measuring the company’s own balance-sheet change. Book equity was 54.8% lower than fiscal 2024 equity of $13.46M, showing how shareholder capital changed year over year. Compared with $11.91M in fiscal 2024, the current cash balance moved 53.1% and finished lower.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $9.42M, showing that operations absorbed cash during the period. Capital spending of $28.00K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Operating cash flow and capital spending combined to leave a $9.45M cash deficit after capital spending. Free-cash-flow margin was -398.4%, reflecting a cash deficit equal to 398.4% of revenue after capital spending. The cash deficit after capital spending represented 87.6% of the period-end asset base. Cash absorbed by operations decreased from $14.09M in fiscal 2024 to $9.42M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.